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Available online xxxxObjective and methods:We investigated the hypothesis that serum low-density lipoprotein cholesterol (LDL-C)
reduction by ezetimibe is associated with the improvement in postprandial hyperlipidemia by performing an
oral fat loading test before and 24 weeks after ezetimibe treatment in diabetic (n = 29) and non-diabetic
(n = 30) male patients with coronary artery disease (CAD).
Results: Serum LDL-C levels were signiﬁcantly reduced by ezetimibe in both groups (diabetic, from 120.3 ± 39.4
to 79.5 ± 23.2 mg/dL, p b 0.001; non-diabetic, from 98.2 ± 41.7 to 76.7 ± 29.2 mg/dL, p b 0.001), and the mean
reduction in serum LDL-Cwas greater in diabetic than non-diabetic patients (−32.0 vs.−19.0%, p= 0.004). The
area under the curve (AUC) for triglyceride (TG) and remnant-like particle cholesterol (RLP-C) decreased
signiﬁcantly in both groups. When compared with the reduction before and after treatment in AUC of TG
(ΔAUC0–6 h TG) and RLP-C (ΔAUC0–6 h RLP-C), they were signiﬁcantly greater in diabetic than non-diabetic pa-
tients (ΔAUC0–6h TG,−28.9 vs.−12.2%, p = 0.028; ΔAUC0–6h RLP-C,−27.8 vs.−12.3%, p = 0.007). In diabetic
patients,ΔAUC0–6 h TGandΔAUC0–6 h RLP-C in thehighest tertile of serumLDL-C reductionwere signiﬁcantly great-
er than those in the lowest tertile (ΔAUC0-6h TG,−34.1 vs.−20.9%, p=0.012;ΔAUC0-6h RLP-C,−34.5 vs.−15.1%,
p = 0.024).
Conclusions: These ﬁndings suggest that serum LDL-C reduction by ezetimibe might be associated with the
improvement of postprandial hyperlipidemia in diabetic patients with CAD.
© 2016 The Author(s). Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Both diabetes mellitus (DM) and hyperlipidemia play important
roles in the development of atherosclerosis and are strong risk fac-
tors for cardiovascular events. There is a strong association between
glucose and lipidmetabolism, and an increase of intestinal cholester-
ol absorption has been reported in DM patients [1]. Postprandial
hyperlipidemia characterized by the accumulation of excess triglyc-
eride (TG)-rich lipoproteins and their hydrolyzed products in a non-
fasting state, has been shown to play an important role in the
progression or vulnerability of coronary arterial plaque [2–4]. Lipidgy, Iwate Prefectural Central
Nakamura).
reland Ltd. This is an open access artimetabolism is signiﬁcantly impaired in DM patients with coronary
artery disease (CAD) compared with non-DM patients with CAD
[5]. Ezetimibe is a lipid-lowering drug that selectively inhibits intes-
tinal cholesterol absorption by binding to Niemann–Pick C1-like 1
(NPC1L1) protein [6]. The administration of this cholesterol trans-
porter inhibitor has been shown to reduce the serum levels of low-
density lipoprotein cholesterol (LDL-C) and fasting TG, especially
when used in combination with other drugs, such as statins [7].
Ezetimibe also improves postprandial hyperlipidemia in patients
with hyperlipidemia [8–10].
It has been reported that the addition of ezetimibe to statin therapy
can induce a greater reduction in serum LDL-C levels in DM patients
compared with non-DM patients [11,12]. However, the mechanism for
this more effective response in DM patients is not clearly understood.
To investigate the hypothesis that the serum LDL-C level reduction
induced by combining ezetimibe and statin therapy is associated with
improvement of postprandial hyperlipidemia, we performed an oral
fat loading test before and 24 weeks after ezetimibe treatment andcle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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patients with CAD.
2. Materials and methods
This study was a 24- week, prospective, open-label, single-center
study to examine the effects of ezetimibe on LDL-C reduction and the re-
lationship with postprandial hyperlipidemia in DM and non-DM male
patients with CAD who were also receiving statin therapy. The study
was conducted according to the principles expressed in the Declaration
of Helsinki. Written informed consent was obtained from the patients
and the study protocol was approved by the ethics committee of the
Iwate Prefectural Central Hospital.
2.1. Study subjects
A total of 65 consecutive type 2 DM and non-DMmale patients (DM
group, n=33; non-DMgroup, n=32)with stable angina pectoris, who
were receiving atorvastatin (10 mg, once daily) had angiographically
conﬁrmed CAD, and who did not meet the exclusion criteria, were en-
rolled in the study. The exclusion criteria were: 1) type 1 DM; 2) type
2 DMwith insulin therapy; 3) bodymass index (BMI) ≥ 25.0; 4) gastro-
intestinal disease limiting drug absorption or partial ileal bypass;
5) major surgery within six months prior to enrollment or concomitant
inﬂammatory disease or malignant tumors; 6) congestive heart failure,
active liver disease, or hepatic dysfunction deﬁned as alanine
aminotransferase or aspartate aminotransferase exceeding the normal
range; 7) concurrent therapy with long-term immunosuppressants;
8) familial hypercholesterolemia; and 9) taking lipid lowering medica-
tions without statins (e.g., cholestyramine, niacin, or ﬁbrates) and/or
eicosapentaenoic acid or docosahexaenoic acid therapy.
2.2. Deﬁnitions
Patients with stable angina pectoris were deﬁned as cardiac is-
chemic patients who had a history of myocardial infarction, coronary
artery bypass, percutaneous coronary intervention with or without
stenting, or a previous angiographically conﬁrmed stenotic lesion
(≥75%) in a major epicardial coronary artery. They were also in
stable condition when chest pain was brought on by exertion,
which was resolved under nitrate-therapy and had unchanged
characteristics (frequency, severity, duration, time of appearance,
and precipitating factors) for the previous 60 days [13]. Diagnosis
of type 2 DM was made according to the criteria in the 2010
American Diabetes Association Guidelines [14]: fasting plasma glu-
cose (FPG) ≥ 126 mg/dL, hemoglobin A1c (HbA1c) ≥ 6.5%, or current
use of hypoglycemic agents. Non-DM patients were deﬁned as
patients with FPG b 100 mg/dL and HbA1c b 5.7% without use of
any hypoglycemic agents. There were no additions or changes to
any of the hypoglycemic or lipid-lowering agents during the period
of this study.
2.3. Study design
Patients were given one high-fat meal between June 2015 and
March 2016 to collect the baseline values. For fat loading, all patients
were given an oral high-fat meal (the “cake sále test”) [5,10,15] before
and 24 weeks after ezetimibe treatment (10 mg, once daily). This
“cake sale” consisted of high-fat and high-glucose food (1003 kcal; pro-
tein, 28.6 g {11.4%}; lipids, 62.4 g {56.0%}; carbohydrate, 80.7 g {32.2%};
cholesterol, 320.5 mg {0.4%}). The ingredients were similar to those of
an American fast-food meal (Big Mac® cheeseburger with French fries
and Coca-Cola®), which is one of the most popular meals in the
world. Patients were asked to eat this high-fat meal (“cake sale”) in
30 min. In all patients, the test was performed for breakfast afterovernight fasting for at least 12 h, and when the patient was in stable
condition.2.4. Measurements
The changes in the lipid proﬁle in the DM and non-DM groups were
compared. Blood samples were obtained by venipuncture during the
fasting state just before the meal and 0, 2, 4, and 6 h after the meal.
Sera were separated immediately after blood collection by low-speed
centrifugation (3000 rpm for 15 min at 4 °C) and stored at −80 °C
until laboratory analysis was conducted. Serum TG levels were
determined by an enzymatic method, serum LDL-C and high-density
lipoprotein cholesterol (HDL-C) levels by a direct method, serum apoli-
poprotein A-I (Apo A-I) and apolipoprotein B (Apo B) levels by an
immunoturbidity method, and serum remnant-like particle cholesterol
(RLP-C) levels by an immunoafﬁnity isolation method at a contract lab-
oratory (SRL Co., Ltd., Tokyo, Japan). Serum LDL-C levels were deter-
mined by direct measurement, not by calculation using the Friedewald
formula, since the postprandial TG levels were expected to exceed
400mg/dL. Plasmaglucose andHbA1c levelswere alsomeasured before
and 24weeks after ezetimibe treatment. HbA1c levels were determined
by a high-performance liquid chromatographymethod at the laboratory
in our hospital. The area under the curve (AUC) of each parameter was
calculated by the trapezoidal method and was compared to an estimate
of the postprandial integrated response of each group during the test.2.5. Statistical analysis
All values were expressed as mean ± standard deviation for
continuous variables and as numbers and percentages for categorical
variables. Differences between two groups were assessed using the
Student's unpaired t-test or Mann–Whitney's U test for continuous var-
iables, and the chi-square test or Fisher's exact test for categorical vari-
ables. One-way analysis of variance, followed by Tukey's honestly
signiﬁcant difference test, was used to examine differences amongmul-
tiple groups. A two-sided p-value of ≤0.05 was considered statistically
signiﬁcant. All statistical analyses were performed with SPSS version
14.0 (SPSS Inc., Chicago, IL, USA).3. Results
3.1. Baseline characteristics in the DM and non-DM groups
Three patients in the DM group and two patients in the non-DM
group did not want to do the oral fat loading test after 24 weeks of
ezetimibe treatment, and one patient in the DM group had restricted
oral intake due to a stroke during the study period. After exclusion
of these patients, 59 patients (DM group, n = 29; non-DM group,
n=30)were included to this analysis, and their baseline characteristics
are shown in Table 1. The levels of HbA1c and FPG were 7.6 ± 1.7%,
127.9 ± 6.1 mg/dL in the DM group; and 5.4 ± 0.2%, 91.8 ±
9.2mg/dL in non-DM group, respectively. All patients received the stat-
in therapy (atorvastatin 10 mg). There were several signiﬁcant differ-
ences between the lipid proﬁles of the DM and non-DM groups. The
serum RLP-C and Apo B levels in the DM group were signiﬁcant higher
than those in the non-DM group (RLP-C: 7.2 ± 3.5 vs. 4.5 ±
2.0 mg/dL, p = 0.008; Apo B: 120.3 ± 23.5 vs. 98.2 ± 15.4 mg/dL,
p = 0.003). The serum LDL-C levels in the DM group were higher com-
pared with the non-DM group, but the difference was not statistically
signiﬁcant (120.3 ± 39.4 vs. 98.2 ± 41.7 mg/dL, p = 0.052). Patients
with BMI ≥ 25.0 were excluded from this study, and therewas no signif-
icant difference in body size. There were also no signiﬁcant differences
in age, blood pressure, smoking, and the incidence of hypertension
between the groups.
Table 1
Baseline characteristics in patients.
Variable Overall (n = 59) DM group (n = 29) Non-DM group (n = 30) p value
Age (years) 66.5 ± 7.7 67.4 ± 7.3 65.8 ± 8.2 0.540
Weight (kg) 62.9 ± 5.8 63.4 ± 5.9 62.0 ± 5.8 0.448
Height (cm) 164.8 ± 4.5 165.3 ± 3.0 164.2 ± 4.9 0.456
Body mass index (kg/m2) 22.9 ± 1.5 23.1 ± 1.4 22.7 ± 1.6 0.745
Hypertension 41 (69%) 21 (72%) 20 (67%) 0.632
Blood pressure
Systolic (mm Hg) 132.8 ± 15.8 137.3 ± 14.4 129.5 ± 16.5 0.333
Diastolic (mm Hg) 73.8 ± 10.7 68.5 ± 11.9 75.6 ± 10.3 0.217
Current or ex-smokers 41 (69%) 22 (76%) 19 (63%) 0.296
Glucose markers
HbA1c (%) 6.5 ± 1.6 7.6 ± 1.7 5.4 ± 0.2 b0.001
Fasting plasma glucose (mg/dL) 109.9 ± 7.8 127.9 ± 6.1 91.8 ± 9.2 b0.001
Lipid markers
Triglyceride (mg/dL) 143.4 ± 74.9 150.5 ± 77.3 121.4 ± 72.5 0.096
LDL cholesterol (mg/dL) 115.0 ± 42.7 120.3 ± 39.4 98.2 ± 41.7 0.052
HDL cholesterol (mg/dL) 48.7 ± 12.6 47.8 ± 11.8 49.6 ± 13.4 0.696
RLP cholesterol (mg/dL) 5.9 ± 3.1 7.2 ± 3.5 4.5 ± 2.0 0.008
Apolipoprotein A-I (mg/dL) 134.9 ± 23.9 140.7 ± 25.1 128.5 ± 17.8 0.139
Apolipoprotein B (mg/dL) 109.4 ± 20.1 120.3 ± 23.5 98.2 ± 15.4 0.003
Values are expressed as either mean ± SD or number (percentage).
DM= diabetes mellitus; HbA1c = hemoglobin A1c; LDL = low-density lipoprotein; HDL = high-density lipoprotein; RLP = remnant lipoprotein.
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There were no changes in lipid- or glucose-lowering medications or
any othermedications during the study period. Neither group showed a
signiﬁcant change in the body weight from the baseline to the 24 week
follow-up examination (DM group, 63.4 ± 5.9 kg at baseline vs. 63.2 ±
5.7 kg at 24 weeks, p = 0.372; non-DM group, 62.0 ± 5.8 kg vs. 62.3 ±
5.5 kg at 24weeks, p=0.218). The levels of HbA1cwere not signiﬁcant-
ly different between baseline and the 24week follow-up in either group
(DMgroup, 7.6±1.7% at baseline vs. 7.7± 1.5% at 24weeks, p=0.537;
non-DMgroup, 5.4±0.2% vs. 5.5±0.4% at 24weeks, p=0.604). Serum
LDL-C levels were signiﬁcantly reduced by ezetimibe treatment in
both groups (DM group, 120.3 ± 39.4 mg/dL at baseline vs. 79.5 ±
23.2 mg/dL at 24 weeks, p b 0.001; non-DM group, 98.2 ± 41.7 mg/dL
at baseline vs. 76.7± 29.2 at 24weeks, p b 0.001) (Fig. 1A), and the per-
cent reduction in serumLDL-C levelswas signiﬁcantly greater in theDM
group than in the non-DM group (−32.0 ± 13.4% vs.−19.0 ± 19.1%,
p = 0.004) (Fig. 1B).Fig. 1. Changes (A) and percentage reduction (B) in serum LDL levels after ezetimibe
treatment. Data are expressed as mean ± SD.3.3. Postprandial lipid metabolism before and after ezetimibe treatment in
the DM and non-DM groups
The changes in the lipid proﬁle during the oral fat loading test before
and after ezetimibe treatment in the DM and non-DM groups are sum-
marized in Table 2. Serum TG and RLP-C levels showed signiﬁcant
changes during the study. Other lipid parameters did not show any
meaningful changes from the baseline. Fig. 2A and B shows the changes
in the serum TG and RLP-C levels before and after the treatment in the
DM and non-DM groups. Serum TG and RLP-C levels before the treat-
ment continued to rise for 6 h after the high fat meal in both groups.
After 24weeks of treatment, ezetimibe signiﬁcantly decreased the base-
line and peak levels for serum TG and RLP-C, and AUC for both markers
between 0 and 6 h decreased signiﬁcantly in both groups (AUC of TG in
DM group, from 2669.9 ± 745.3 to 1302.9 ± 377.3 mg/dL at 6 h,
p b 0.001; AUC of TG in non-DM group, from 1876.8 ± 445.3 to
1109.2 ± 352.1 mg/dL at 6 h, p = 0.005; AUC of RLP-C in DM group,
from 91.9 ± 28.3 to 44.2 ± 14.6 mg/dL at 6 h, p b 0.001; AUC of RLP-C
in non-DM group, from 62.4 ± 20.4 to 36.2 ± 10.9 mg/dL at 6 h,
p = 0.007). The percent reductions in AUC of serum TG (ΔAUC0–6 h TG)
and RLP-C (ΔAUC0–6 h RLP-C) during the study period were signiﬁcantly
greater in the DM group than in non-DM group (ΔAUC0–6 h TG,−28.9±
20.5% vs.−12.2± 22.0%, p=0.028;ΔAUC0–6h RLP-C,−27.8± 15.5% vs.
−12.3 ± 16.0%, p = 0.007) (Fig. 2C and D).3.4. Association between reduction of the serum LDL-C levels and
improvement in postprandial hyperlipidemia after ezetimibe treatment in
the DM group
When the patients in the DM group were divided into tertiles ac-
cording to the percent reduction of serum LDL-C level before and after
the treatment, the ΔAUC0–6 h TG and ΔAUC0–6 h RLP-C in the highest
tertile (from−36.0 to−61.9%, respectively, n= 10) were signiﬁcantly
greater than those in the lowest tertile (from −6.7 to −22.3%,
Table 2
Changes of lipid parameters after the oral fat loading test.
Before
After
0 h 2 h 4 h 6 h
Triglyceride (mg/dL)
DM group; ezetimibe (−) 150.5 ± 77.3 154.8 ± 92.7 234.7 ± 75.6 375.9 ± 113.2ǁ 394.1 ± 117.6ǁ
DM group; ezetimibe (+) 121.8 ± 73.3 125.3 ± 45.2 165.7 ± 66.4 235.2 ± 75.2† 225.8 ± 54.7†
Non-DM group; ezetimibe (−) 121.4 ± 72.5 125.8 ± 75.7 195.3 ± 81.5 267.4 ± 105.8‡ 271.2 ± 126.7‡
Non-DM group; ezetimibe (+) 89.5 ± 32.8 90.4 ± 32.8 136.4 ± 45.8 203.4 ± 75.6† 173.2 ± 79.7†
RLP cholesterol (mg/dL)
DM group; ezetimibe (−) 7.2 ± 3.5 7.0 ± 3.3 11.1 ± 4.0 18.3 ± 5.8ǁ 22.7 ± 7.4ǁ
DM group; ezetimibe (+) 3.2 ± 0.9 3.2 ± 0.9 6.0 ± 1.9 9.2 ± 3.6‡ 8.9 ± 3.9†
Non-DM group; ezetimibe (−) 4.5 ± 2.0 4.5 ± 1.9 8.0 ± 3.0 12.5 ± 4.0§ 14.4 ± 6.4§
Non-DM group; ezetimibe (+) 2.6 ± 0.6 2.7 ± 0.8 4.9 ± 1.5 7.5 ± 2.7† 7.3 ± 3.5†
LDL cholesterol (mg/dL)
DM group; ezetimibe (−) 120.3 ± 39.4 122.5 ± 40.3 119.5 ± 37.5 117.8 ± 30.9 120.4 ± 36.2
DM group; ezetimibe (+) 79.5 ± 23.2 78.9 ± 22.8 75.3 ± 21.5 72.6 ± 22.7 73.7 ± 21.8
Non-DM group; ezetimibe (−) 98.2 ± 41.7 100.6 ± 40.6 95.5 ± 38.8 92.3 ± 38.5 93.7 ± 37.9
Non-DM group; ezetimibe (+) 76.7 ± 29.2 76.1 ± 27.3 71.4 ± 25.7 70.7 ± 25.5 71.4 ± 26.8
HDL cholesterol (mg/dL)
DM group; ezetimibe (−) 47.8 ± 11.8 49.3 ± 11.8 46.0 ± 11.4 44.4 ± 10.9 45.1 ± 12.1
DM group; ezetimibe (+) 51.9 ± 12.8 52.4 ± 11.9 48.9 ± 12.0 47.3 ± 12.2 47.3 ± 12.3
Non-DM group; ezetimibe (−) 49.6 ± 13.4 50.7 ± 13.0 46.4 ± 12.3 45.3 ± 12.9 45.8 ± 13.7
Non-DM group; ezetimibe (+) 50.2 ± 11.3 51.2 ± 11.6 47.2 ± 10.5 46.3 ± 10.7 46.8 ± 11.0
Apolipoprotein A-I (mg/dL)
DM group; ezetimibe (−) 140.7 ± 25.1 144.8 ± 23.8 137.8 ± 24.6 135.1 ± 22.5 137.2 ± 23.8
DM group; ezetimibe (+) 139.6 ± 24.8 143.5 ± 24.1 139.2 ± 23.8 137.3 ± 24.1 139.3 ± 23.6
Non-DM group; ezetimibe (−) 128.5 ± 17.8 129.4 ± 18.9 122.9 ± 17.9 123.5 ± 18.6 125.6 ± 20.1
Non-DM group; ezetimibe (+) 128.1 ± 18.9 131.2 ± 17.9 124.8 ± 18.1 125.4 ± 19.3 127.7 ± 20.5
Apolipoprotein B (mg/dL)
DM group; ezetimibe (−) 120.3 ± 23.5 122.7 ± 21.3 117.9 ± 25.3 117.4 ± 21.6 118.2 ± 20.9
DM group; ezetimibe (+) 103.0 ± 22.1 105.4 ± 19.3 101.9 ± 20.3 102.4 ± 19.7 103.0 ± 23.1
Non-DM group; ezetimibe (−) 98.2 ± 15.4 99.1 ± 16.4 95.0 ± 15.1 95.7 ± 14.0 97.5 ± 14.6
Non-DM group; ezetimibe (+) 88.3 ± 15.8 88.1 ± 15.6 85.5 ± 17.8 85.6 ± 15.1 87.7 ± 16.3
Values are expressed as mean ± SD.
†p b 0.05, ‡p b 0.01, §p b 0.005, ǁp b 0.001 comparing with the value before the loading test in the same group.
DM= diabetes mellitus; RLP = remnant lipoprotein; LDL = low-density lipoprotein; HDL = high-density lipoprotein.
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p = 0.012; ΔAUC0–6 h RLP-C, −34.5 ± 23.1 vs. −15.1 ± 14.6%, p =
0.024) (Fig. 3A and B). In comparison ΔAUC0–6 h TG and RLP-C were
not signiﬁcantly different between the highest (from−29.0 to−51.8%,
respectively, n = 10) and lowest (from +24.8 to−10.3%, respectively,
n = 10) tertiles in the non-DM group (AUC0–6 h TG,−17.0 ± 19.8 vs.
−11.8 ± 8.3%, p = 0.225; ΔAUC0–6 h RLP-C, −17.1 ± 30.1vs.
−13.7 ± 13.8%, p = 0.406).
4. Discussion
There are three major ﬁndings of this study. First, diabetic CAD
patients experienced a greater reduction in serum LDL-C levels
after ezetimibe treatment than non-diabetic CAD patients. Secondly,
there was greater improvement in postprandial hyperlipidemia after
ezetimibe treatment in diabetic compared with non- diabetic CAD
patients. Thirdly, the highest tertile of LDL reduction after ezetimibe
treatment showed a signiﬁcant improvement in postprandial hyperlip-
idemia compared with the lowest tertile in diabetic CAD patients, but
not in non-diabetic CAD patients. These ﬁndings suggested that the en-
hanced LDL-C reduction by ezetimibe in diabetic CAD patients might be
associated with the improvement in postprandial hyperlipidemia.
It is well known that the addition of ezetimibe to statin therapy
can achieve a greater reduction in serum LDL-C levels compared
to statin monotherapy [16,17]. However, the potential effects of
ezetimibe have not been extensively evaluated, and little informa-
tion is available about diabetic patients with hyperlipidemia.
Nakajima et al. [11] reported the effect of the addition of ezetimibe
to a statin on coronary plaque regression, estimated by intravascular
ultrasound in patients with acute coronary syndrome (ZEUS trial).
They found that the reduction of both serum LDL-C levels and plaque
volume were signiﬁcantly greater in diabetic patients comparedwith non-diabetic patients. We also found that the addition of
ezetimibe to statin therapy induced a greater reduction in serum
LDL-C levels in diabetic CAD patients compared with non-diabetic
CAD patients. Thus, diabetic patients may be more likely to beneﬁt
from the addition of ezetimibe to statin therapy.
Postprandial hyperlipidemia is characterized by the accumulation of
excess TG-rich lipoproteins and their partially hydrolyzed products
such as chylomicron (CM) remnant and very low-density lipoprotein
(VLDL) remnant during the postprandial period, and is a predisposing
factor in cardiovascular events [4,18]. Therefore, the inhibition of in-
creased cholesterol not only in a fasting state but also in a postprandial
state is an additional strategy for serum LDL-C reduction for patients in
whom the therapeutic effect of statin monotherapy is insufﬁcient. Al-
though endogenous and exogenous cholesterol pathways can induce
postprandial lipid accumulations, the activated exogenous pathway
seems to be more strongly related with postprandial hyperlipidemia.
Masuda et al. [19] measured Apo B-48 and Apo B-100 levels separately
in the fasting and postprandial states to assess the endogenous and ex-
ogenous pathways independently. They reported that the postprandial
increase in serum TG and RLP-C levels was mainly due to increases of
CM and CM remnant, but not VLDL and VLDL remnant. In diabetic pa-
tients, the following have been demonstrated: 1) increased expression
of NPC1L1, which facilitates cholesterol absorption in the small intes-
tine; 2) decreased expression of adenosine triphosphate (ATP-) binding
cassette transporters G5 and G8 (ABCG5, ABCG8), which bring choles-
terol to the small intestinal lumen from small intestinal epithelial
cells; and 3) increased microsomal TG transfer protein (MTP), which
packages the CM particle by assembling cholesterol, TG, phospholipids
and Apo B48 [20]. These alterations to the expression of intestinal
genes could result in increased cholesterol absorption and lead to eleva-
tion of serum LDL-C levels in diabetic patients. Consistentwith previous
reports [2,21], our study indicates that the magnitude of postprandial
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or RLP-C, respectively, was greater in diabetic CAD patients than in non-
diabetic CAD patients.
Recently, some studies have reported that the addition of ezetimibe,
a NPC1L1 protein inhibitor, to statin therapy improved postprandial hy-
perlipidemia [8,9]. However, little is known about the differences in
ezetimibe treatment in diabetic patients compared with non-diabetic
patients. One purpose of this study was to investigate whether the im-
provement of postprandial hyperlipidemia by ezetimibe treatment
was greater in CAD patients with DM compared with those without
DM. Our study showed signiﬁcantly greater postprandial TG or RLP-C
reduction after ezetimibe treatment in diabetic CAD patients compared
with non-diabetic CADpatients. To the best of our knowledge, this is the
ﬁrst study to investigate the effectiveness of combination therapy with
ezetimibe and a statin (atorvastatin) for the management of postpran-
dial hyperlipidemia in CAD patients with DM.
Another important ﬁnding of this study was that CAD patents in the
highest tertile of LDL-C reduction by ezetimibe treatment demonstrated
a greater reduction in AUC for TG and RLP-C in the diabetic group, but
not in the non-diabetic group. In non-diabetic patients, inwhom the ex-
pression of NPC1L1 protein has not been enhanced in the intestine, the
possibility exists that ezetimibe reduces hepatic cholesterol by inhibi-
tion of NPC1L1 protein activity not only in the intestine, but also in the
liver [22]. Measurement of lipid markers associated with the endoge-
nous pathway, such as VLDL cholesterol, VLDL remnant, and Apo B-
100, would contribute to a better understanding of the differences in
the effect of ezetimibe between diabetic and non-diabetic CAD patients.
5. Study limitations
There were several limitations to this study. First, the study only in-
cludedmales to exclude the hormonal effect of estrogen on postprandi-
al lipid metabolism. Second, this study did not include patients taking
insulin therapy to eliminate the effects of exogenous insulin. The effect
of ezetimibe on postprandial lipid metabolism remains unknown in
these patients. Third, all patients had CAD and were treated with the
same dose of atorvastatin with ezetimibe. It remains unknownwhether
similar resultswould be obtainedwith other statins or different doses of
atorvastatin.
6. Conclusions
The addition of ezetimibe to statin therapy induced a greater reduc-
tion in the serum LDL-C levels in diabetic compared with non-diabetic
CAD patients. This enhanced LDL-C lowering effect by ezetimibe treat-
ment might be accomplished with the improvement of postprandial
hyperlipidemia in diabetic CAD patients.Conﬂict of interest
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